Researchers from Department of Cell and Tissue Engineering Discuss Findings in Breast Cancer (Combination treatment of tamoxifen with risperidone in breast cancer)
By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Oncology have been published. According to news reporting originating in Changhua, Taiwan, by NewsRx journalists, research stated, "Tamoxifen has long been used and still is the most commonly used endocrine therapy for treatment of both early and advanced estrogen receptor-positive breast cancer in pre-and post-menopause women. Tamoxifen exerts its cytotoxic effect primarily through cytostasis which is associated with the accumulation of cells in the G0/G1 phase of the cell cycle."
The news reporters obtained a quote from the research from the Department of Cell and Tissue Engineering, "Apoptotic activity can also be exerted by tamoxifen which involves cleavage of caspase 9, caspase 7, caspase 3, and poly-ADP-ribose polymerase (PARP). Down-regulation of anti-apoptotic proteins Bcl-2 and Bcl-xL and up-regulation of pro-apoptotic proteins Bax and Bak have also been observed. In addition, stress response protein of GRP 94 and GRP 78 have also been induced by tamoxifen in our study. However, side effects occur during tamoxifen treatment in breast cancer patients. Researching into combination regimen of tamoxifen and drug(s) that relieves tamoxifen-induced hot flushes is important, because drug interactions may decrease tamoxifen efficacy. Risperidone has been shown to be effective in reducing or eliminating hot flushes on women with hormonal variations. In this present study, we demonstrated that combination of tamoxifen with risperidone did not interfered tamoxifen-induced cytotoxic effects in both in vitro and in vivo models, while fluoxetine abrogated the effects of tamoxifen."
According to the news reporters, the research concluded: "This is the first paper suggesting the possibility of combination treatment of tamoxifen with risperidone in breast cancer patients, providing a conceivable resolution of tamoxifen-induced side effects without interfering the efficacy of tamoxifen against breast cancer."
For more information on this research see: Combination treatment of tamoxifen with risperidone in breast cancer. Plos One, 2014;9(6):e98805. (Public Library of Science - www.plos.org; Plos One - www.plosone.org)
Our news correspondents report that additional information may be obtained by contacting W.L. Yeh, Dept. of Cell and Tissue Engineering, Changhua Christian Hospital, Changhua, Taiwan. Additional authors for this research include H.Y. Lin, H.M. Wu and D.R Chen (see also Oncology).
Keywords for this news article include: Asia, Taiwan, Caspase, Changhua, Oncology, Breast Cancer, Women's Health, Enzymes and Coenzymes.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC